Kairos Pharma (KAPA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 May, 2026Executive summary
The 2026 Annual Meeting of Stockholders is scheduled for June 29, 2026, and will be held virtually, allowing online participation by shareholders.
The proxy statement was supplemented to correct the record date for voting eligibility to May 18, 2026.
Voting matters and shareholder proposals
Only shareholders of record as of May 18, 2026, are entitled to vote at the 2026 Annual Meeting and any adjournments.
The meeting agenda and proposals are detailed in the proxy statement and its supplement.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kairos Pharma
- Lead antibody ENV105 targets drug resistance in cancer, with key trial readouts expected soon.KAPA
Maxim Group’s 2024 Healthcare Virtual Summit8 Jul 2026 - All proposals, including director elections and equity plan amendments, were approved by stockholders.KAPAAGM 202629 Jun 2026
- Virtual meeting to vote on directors, auditor, reverse split, and expanded equity plan.KAPAProxy filing22 May 2026
- Advancing drug resistance therapies with major 2026 clinical and partnership milestones ahead.KAPA16th Annual LD Micro Invitational Conference18 May 2026
- ENV105 and KROS 741 advance in trials to address cancer resistance, backed by strong funding.KAPAInvestor presentation18 May 2026
- Q1 2026 net loss widened to $1.65M, cash at $3.68M, with new financing and manufacturing deals.KAPAQ1 202613 May 2026
- Stockholders will vote on director elections, a reverse split, auditor ratification, and equity plan changes.KAPAProxy filing11 May 2026
- Net loss rose to $5.4M in 2025; cash of $4.5M may not fund operations for 12 months.KAPAQ4 202531 Mar 2026
- Novel antibody therapies aim to overcome cancer drug resistance, with key data expected in 2025.KAPA17th Annual LD Micro Main Event Conference17 Jan 2026